PubMed for Bookshelf ID: 5413050

Year	Number of Results
2015	1
2017	1
2018	1
2019	3
2020	4
2022	2
2023	1
2024	0

1

Viltolarsen: From Preclinical Studies to FDA Approval.

Roshmi RR, Yokota T. Roshmi RR, et al. Methods Mol Biol. 2023;2587:31-41. doi: 10.1007/978-1-0716-2772-3_2. Methods Mol Biol. 2023. PMID: 36401022

2

Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy.

Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, McDonald CM, Smith EC, Zaidman CM, Nakagawa T; CINRG DNHS Investigators; Hoffman EP. Clemens PR, et al. J Neuromuscul Dis. 2022;9(4):493-501. doi: 10.3233/JND-220811. J Neuromuscul Dis. 2022. PMID: 35634851 Free PMC article. Clinical Trial.

3

Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.

Alhamadani F, Zhang K, Parikh R, Wu H, Rasmussen TP, Bahal R, Zhong XB, Manautou JE. Alhamadani F, et al. Drug Metab Dispos. 2022 Jun;50(6):879-887. doi: 10.1124/dmd.121.000418. Epub 2022 Feb 27. Drug Metab Dispos. 2022. PMID: 35221289 Free PMC article. Review.

4

Viltolarsen (Viltepso) for Duchenne muscular dystrophy.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Oct 19;62(1609):167. Med Lett Drugs Ther. 2020. PMID: 33429411 No abstract available.

5

Viltolarsen: First Approval.

Dhillon S. Dhillon S. Drugs. 2020 Jul;80(10):1027-1031. doi: 10.1007/s40265-020-01339-3. Drugs. 2020. PMID: 32519222 Review.

6

Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.

Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, McDonald CM, Zaidman CM, Morgenroth LP, Osaki H, Satou Y, Yamashita T, Hoffman EP; CINRG DNHS Investigators. Clemens PR, et al. JAMA Neurol. 2020 Aug 1;77(8):982-991. doi: 10.1001/jamaneurol.2020.1264. JAMA Neurol. 2020. PMID: 32453377 Free PMC article. Clinical Trial.

7

Golodirsen: First Approval.

Heo YA. Heo YA. Drugs. 2020 Feb;80(3):329-333. doi: 10.1007/s40265-020-01267-2. Drugs. 2020. PMID: 32026421 Review.

8

Therapeutic developments for Duchenne muscular dystrophy.

Verhaart IEC, Aartsma-Rus A. Verhaart IEC, et al. Nat Rev Neurol. 2019 Jul;15(7):373-386. doi: 10.1038/s41582-019-0203-3. Nat Rev Neurol. 2019. PMID: 31147635 Review.

9

The current state and future directions of RNAi-based therapeutics.

Setten RL, Rossi JJ, Han SP. Setten RL, et al. Nat Rev Drug Discov. 2019 Jun;18(6):421-446. doi: 10.1038/s41573-019-0017-4. Nat Rev Drug Discov. 2019. PMID: 30846871 Review.

10

Treating Disease at the RNA Level with Oligonucleotides.

Levin AA. Levin AA. N Engl J Med. 2019 Jan 3;380(1):57-70. doi: 10.1056/NEJMra1705346. N Engl J Med. 2019. PMID: 30601736 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

13 results

Results by year